TN2015000045A1 - Tris(hetero)arylpyrazoles and use thereof - Google Patents
Tris(hetero)arylpyrazoles and use thereofInfo
- Publication number
- TN2015000045A1 TN2015000045A1 TNP2015000045A TN2015000045A TN2015000045A1 TN 2015000045 A1 TN2015000045 A1 TN 2015000045A1 TN P2015000045 A TNP2015000045 A TN P2015000045A TN 2015000045 A TN2015000045 A TN 2015000045A TN 2015000045 A1 TN2015000045 A1 TN 2015000045A1
- Authority
- TN
- Tunisia
- Prior art keywords
- hetero
- arylpyrazoles
- tris
- treating
- preparation
- Prior art date
Links
- JUHMHPOXZAYYJP-UHFFFAOYSA-N ethyl 5-amino-1-(4-methylphenyl)sulfonylpyrazole-4-carboxylate Chemical class NC1=C(C(=O)OCC)C=NN1S(=O)(=O)C1=CC=C(C)C=C1 JUHMHPOXZAYYJP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000007983 Tris buffer Substances 0.000 title 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012016908.6A DE102012016908A1 (de) | 2012-08-17 | 2012-08-17 | Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung |
| PCT/EP2013/067201 WO2014027112A1 (de) | 2012-08-17 | 2013-08-16 | Tris-(hetero)aryl-pyrazole und ihre verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2015000045A1 true TN2015000045A1 (en) | 2016-06-29 |
Family
ID=48986151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2015000045A TN2015000045A1 (en) | 2012-08-17 | 2015-02-12 | Tris(hetero)arylpyrazoles and use thereof |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9249148B2 (enExample) |
| EP (1) | EP2885300A1 (enExample) |
| JP (1) | JP2015524835A (enExample) |
| KR (1) | KR20150042841A (enExample) |
| CN (1) | CN104684913B (enExample) |
| AP (1) | AP2015008325A0 (enExample) |
| AR (1) | AR092145A1 (enExample) |
| AU (1) | AU2013303993A1 (enExample) |
| BR (1) | BR112015003115A2 (enExample) |
| CA (1) | CA2881997A1 (enExample) |
| CL (1) | CL2015000362A1 (enExample) |
| CU (1) | CU20150015A7 (enExample) |
| DE (1) | DE102012016908A1 (enExample) |
| EA (1) | EA201500232A1 (enExample) |
| HK (1) | HK1212327A1 (enExample) |
| IL (1) | IL237298A0 (enExample) |
| MA (1) | MA37928A1 (enExample) |
| MX (1) | MX2015002046A (enExample) |
| NZ (1) | NZ704727A (enExample) |
| PE (1) | PE20150869A1 (enExample) |
| PH (1) | PH12015500322B1 (enExample) |
| SG (1) | SG11201501183VA (enExample) |
| TN (1) | TN2015000045A1 (enExample) |
| TW (1) | TW201412720A (enExample) |
| UA (1) | UA112488C2 (enExample) |
| WO (1) | WO2014027112A1 (enExample) |
| ZA (1) | ZA201501078B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012016908A1 (de) | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung |
| AR099428A1 (es) * | 2014-02-14 | 2016-07-20 | Aicuris Gmbh & Co Kg | Combinaciones de principios activos farmacéuticos con compuestos basados en tri(hetero)aril pirazoles |
| EP3263567A1 (en) * | 2016-07-01 | 2018-01-03 | AiCuris Anti-infective Cures GmbH | Carboxamide-substituted pyrazoles and tri(hetero)aryl-pyrazoles for use in methods of treating and / or preventing cardiovascular diseases and / or comorbidities thereof |
| WO2019194207A1 (ja) * | 2018-04-04 | 2019-10-10 | 日本たばこ産業株式会社 | ヘテロアリールで置換されたピラゾール化合物及びその医薬用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| IL104311A (en) | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US6277847B1 (en) | 1999-04-02 | 2001-08-21 | Fmc Corporation | Herbicidal isoindolinonyl-and 3,4-dihydroisoquinolonyl-substituted heterocycles |
| WO2003037274A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| US6649638B1 (en) * | 2002-08-14 | 2003-11-18 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| CA2505945A1 (en) | 2002-12-02 | 2004-06-17 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives useful as cox-i inhibitors |
| KR20050096956A (ko) | 2003-02-07 | 2005-10-06 | 다이이찌 세이야꾸 가부시기가이샤 | 피라졸 유도체 |
| EP1718617B1 (en) | 2004-02-20 | 2009-08-19 | AstraZeneca AB | 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators |
| AU2005225524B2 (en) | 2004-03-26 | 2007-11-22 | F. Hoffmann-La Roche Ag | Tetrahydrocarbazoles and derivatives |
| EP1762568A1 (en) | 2004-07-01 | 2007-03-14 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives |
| GB0417910D0 (en) | 2004-08-11 | 2004-09-15 | Novartis Ag | Organic compounds |
| DE102004054666A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| WO2007002559A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
| EP1743637A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome |
| WO2007009701A2 (en) | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome |
| GB0516661D0 (en) | 2005-08-13 | 2005-09-21 | Astrazeneca Ab | Therapeutic agents |
| JP5341516B2 (ja) | 2005-09-13 | 2013-11-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ２−アニリン−４−アリール置換チアゾール誘導体 |
| WO2007064553A2 (en) | 2005-11-29 | 2007-06-07 | Merck & Co., Inc. | Thiazole derivatives as cxcr3 receptor modulators |
| US20110195110A1 (en) | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
| JP2010500336A (ja) | 2006-08-09 | 2010-01-07 | ファイザー・プロダクツ・インク | 炭酸脱水酵素阻害剤として有用な複素環 |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
| JP4994295B2 (ja) * | 2007-04-20 | 2012-08-08 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US8648085B2 (en) | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
| AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| AU2009216825A1 (en) | 2008-02-18 | 2009-08-27 | F. Hoffmann-La Roche Ag | 4, 5-dihydro-oxazol-2-yl amine derivatives |
| DE102008015032A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte Pyrazolamide und ihre Verwendung |
| DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| WO2011033018A1 (en) | 2009-09-17 | 2011-03-24 | Janssen Pharmaceutica Nv | Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines |
| ES2607952T3 (es) | 2009-11-13 | 2017-04-04 | Merck Serono S.A. | Derivados tricíclicos de Pirazol Amina |
| WO2012009009A2 (en) * | 2010-07-14 | 2012-01-19 | Addex Pharma S.A. | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| WO2012058133A1 (en) * | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Isoindolinone pde10 inhibitors |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| DE102012016908A1 (de) | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung |
| AR099428A1 (es) | 2014-02-14 | 2016-07-20 | Aicuris Gmbh & Co Kg | Combinaciones de principios activos farmacéuticos con compuestos basados en tri(hetero)aril pirazoles |
-
2012
- 2012-08-17 DE DE102012016908.6A patent/DE102012016908A1/de not_active Withdrawn
-
2013
- 2013-08-15 AR ARP130102907A patent/AR092145A1/es unknown
- 2013-08-16 HK HK15112600.0A patent/HK1212327A1/xx unknown
- 2013-08-16 PE PE2015000171A patent/PE20150869A1/es not_active Application Discontinuation
- 2013-08-16 BR BR112015003115A patent/BR112015003115A2/pt not_active IP Right Cessation
- 2013-08-16 NZ NZ704727A patent/NZ704727A/en not_active IP Right Cessation
- 2013-08-16 US US14/422,191 patent/US9249148B2/en not_active Expired - Fee Related
- 2013-08-16 SG SG11201501183VA patent/SG11201501183VA/en unknown
- 2013-08-16 EA EA201500232A patent/EA201500232A1/ru unknown
- 2013-08-16 EP EP13750087.2A patent/EP2885300A1/de not_active Withdrawn
- 2013-08-16 MX MX2015002046A patent/MX2015002046A/es unknown
- 2013-08-16 TW TW102129567A patent/TW201412720A/zh unknown
- 2013-08-16 JP JP2015527004A patent/JP2015524835A/ja not_active Ceased
- 2013-08-16 AU AU2013303993A patent/AU2013303993A1/en not_active Abandoned
- 2013-08-16 CN CN201380044128.1A patent/CN104684913B/zh not_active Expired - Fee Related
- 2013-08-16 AP AP2015008325A patent/AP2015008325A0/xx unknown
- 2013-08-16 WO PCT/EP2013/067201 patent/WO2014027112A1/de not_active Ceased
- 2013-08-16 MA MA37928A patent/MA37928A1/fr unknown
- 2013-08-16 CA CA2881997A patent/CA2881997A1/en not_active Abandoned
- 2013-08-16 KR KR20157006414A patent/KR20150042841A/ko not_active Withdrawn
- 2013-08-16 UA UAA201502210A patent/UA112488C2/uk unknown
-
2015
- 2015-02-12 TN TNP2015000045A patent/TN2015000045A1/fr unknown
- 2015-02-13 PH PH12015500322A patent/PH12015500322B1/en unknown
- 2015-02-16 ZA ZA2015/01078A patent/ZA201501078B/en unknown
- 2015-02-16 CL CL2015000362A patent/CL2015000362A1/es unknown
- 2015-02-17 IL IL237298A patent/IL237298A0/en unknown
- 2015-02-17 CU CUP2015000015A patent/CU20150015A7/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9249148B2 (en) | 2016-02-02 |
| KR20150042841A (ko) | 2015-04-21 |
| ZA201501078B (en) | 2017-11-29 |
| BR112015003115A2 (pt) | 2017-07-04 |
| DE102012016908A1 (de) | 2014-02-20 |
| CU20150015A7 (es) | 2015-11-27 |
| AP2015008325A0 (en) | 2015-03-31 |
| AR092145A1 (es) | 2015-03-25 |
| CL2015000362A1 (es) | 2015-07-10 |
| EA201500232A1 (ru) | 2015-07-30 |
| PH12015500322B1 (en) | 2019-03-25 |
| MA37928A1 (fr) | 2017-11-30 |
| UA112488C2 (uk) | 2016-09-12 |
| TW201412720A (zh) | 2014-04-01 |
| AU2013303993A1 (en) | 2015-03-12 |
| CN104684913B (zh) | 2016-11-23 |
| WO2014027112A1 (de) | 2014-02-20 |
| PH12015500322A1 (en) | 2015-03-30 |
| CN104684913A (zh) | 2015-06-03 |
| HK1212327A1 (en) | 2016-06-10 |
| MX2015002046A (es) | 2015-06-05 |
| PE20150869A1 (es) | 2015-05-27 |
| IL237298A0 (en) | 2015-04-30 |
| CA2881997A1 (en) | 2014-02-20 |
| NZ704727A (en) | 2016-07-29 |
| US20150203500A1 (en) | 2015-07-23 |
| JP2015524835A (ja) | 2015-08-27 |
| SG11201501183VA (en) | 2015-05-28 |
| EP2885300A1 (de) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| ECSP14013284A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| GB201209613D0 (en) | New compounds | |
| EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
| MX2015005831A (es) | Antagonistas de il-6 y usos de los mismos. | |
| MX349004B (es) | Nuevos compuestos. | |
| PE20151023A1 (es) | Triazolopirazinas | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX349802B (es) | Uso de aril- y hetarilcarboxamidas como endoparasiticidas. | |
| MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| TN2015000045A1 (en) | Tris(hetero)arylpyrazoles and use thereof | |
| SG10201900954SA (en) | Heterocycles as Modulators of Kinase Activity | |
| MX361773B (es) | Agentes de ligación a tlr3. | |
| PH12014502065A1 (en) | Vesicular formulations |